Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

855 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine-A Study Protocol.
Chopra A, Chavan-Gautam P, Tillu G, Saluja M, Borse S, Sarmukaddam S, Chaudhuri S, Rao B, Yadav B, Srikanth N, Patwardhan B. Chopra A, et al. Among authors: yadav b. Front Med (Lausanne). 2022 Mar 29;9:888928. doi: 10.3389/fmed.2022.888928. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35433723 Free PMC article.
AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India.
Singh H, Srivastava S, Yadav B, Rai AK, Jameela S, Muralidharan S, Mohan R, Chaudhary S, Singhal R, Rana R, Khanduri S, Sharma BS, Chandrasekhararao B, Srikanth N, Chaturvedi S. Singh H, et al. Among authors: yadav b. Complement Ther Med. 2022 Jun;66:102814. doi: 10.1016/j.ctim.2022.102814. Epub 2022 Feb 8. Complement Ther Med. 2022. PMID: 35149205 Free PMC article. Clinical Trial.
Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine-A Study Protocol.
Chopra A, Chavan-Gautam P, Tillu G, Saluja M, Borse S, Sarmukaddam S, Chaudhuri S, Rao B, Yadav B, Srikanth N, Patwardhan B. Chopra A, et al. Among authors: yadav b. Front Med (Lausanne). 2022 Feb 16;9:761655. doi: 10.3389/fmed.2022.761655. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35252231 Free PMC article.
Efficacy and safety of Guduchighana Vati in asymptomatic and mild-to-moderate cases of coronavirus disease-19: A randomized controlled pilot study.
Shukla U, Ujjaliya N, Gupta P, Khare V, Yadav B, Rai AK, Amin H, Rana R, Tripathi A, Khanduri S, Sharma BS, Chandrasekhararao B, Srikanth N, Dhiman KS. Shukla U, et al. Among authors: yadav b. Ayu. 2020 Jul-Sep;41(3):188-196. doi: 10.4103/ayu.ayu_11_21. Epub 2022 Feb 24. Ayu. 2020. PMID: 35370379 Free PMC article.
Disease Characteristics, Care-Seeking Behavior, and Outcomes Associated With the Use of AYUSH-64 in COVID-19 Patients in Home Isolation in India: A Community-Based Cross-Sectional Analysis.
Srikanth N, Kumar A, Chandrasekhararao B, Singhal R, Yadav B, Khanduri S, Jameela S, Rai AK, Tripathi A, Rana R, Ahmad A, Sharma BS, Jaiswal A, Kotecha R; State Level Collaborators. Srikanth N, et al. Among authors: yadav b. Front Public Health. 2022 Jul 6;10:904279. doi: 10.3389/fpubh.2022.904279. eCollection 2022. Front Public Health. 2022. PMID: 35900336 Free PMC article.
Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial.
Chopra A, Tillu G, Chuadhary K, Reddy G, Srivastava A, Lakdawala M, Gode D, Reddy H, Tamboli S, Saluja M, Sarmukaddam S, Gundeti M, Raut AK, Rao BCS, Yadav B, Srikanth N, Patwardhan B. Chopra A, et al. Among authors: yadav b. PLoS One. 2023 Mar 16;18(3):e0282688. doi: 10.1371/journal.pone.0282688. eCollection 2023. PLoS One. 2023. PMID: 36928877 Free PMC article. Clinical Trial.
855 results